{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-059379","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2021-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.440430+00:00","generated_at":"2026-06-28T03:33:02.788086+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bolt Biotherapeutics reports interim Phase 1/2 BDC-1001 data: safe, 1 durable PR at 52 weeks, no CRS","bullets":["BDC-1001 showed favorable safety in 57 patients; no dose-limiting toxicities up to 20 mg/kg Q3W and 12 mg/kg Q2W.","One durable partial response maintained through 52 weeks; multiple patients with stable disease >12 weeks in 40 evaluable subjects.","No cytokine release syndrome (CRS) observed; maximum tolerated dose not yet reached.","Plasma/tissue biomarkers confirm TLR7/8 activation and myeloid cell infiltration consistent with mechanism of action.","Company plans to continue monotherapy dose escalation, evaluate weekly dosing, and initiate combination with nivolumab by year-end 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-059379","json":"https://secwatch.observer/filing/0001564590-21-059379.json","markdown":"https://secwatch.observer/filing/0001564590-21-059379.md","text":"https://secwatch.observer/filing/0001564590-21-059379.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021059379/0001564590-21-059379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021059379/bolt-8k_20211206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T03:33:02.788086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}